Andrew von Eschenbach
Director/Board Member en BAUSCH + LOMB CORPORATION .
Fortuna: 595 534 $ al 31/03/2024
Perfil
Dr. Andrew C.
von Eschenbach, MD, is an Independent Director at TriSalus Life Sciences, Inc., an Independent Director at Viamet Pharmaceuticals Corp., a President at Samaritan Health Initiatives, Inc. and an Independent Director at Bausch + Lomb Corp.
He is on the Board of Directors at TriSalus Life Sciences, Inc., Wavebreak Therapeutics Ltd., Reagan-udall Foundation, Viamet Pharmaceuticals Corp., Viamet Pharmaceuticals, Inc., Focused Ultrasound Foundation, Banyan Biomarkers, Inc., Innocrin Pharmaceuticals Holdings LLC, Innocrin Pharmaceuticals, Inc., National Comprehensive Cancer Network Foundation, Bausch & Lomb, Inc. and Bausch + Lomb Corp.
Dr. von Eschenbach was previously employed as an Independent Director by Celularity, Inc., an Independent Director by Radius Health, Inc., an Independent Director by Bausch Health Cos., Inc., an Independent Director by Asterias Biotherapeutics, Inc., an Independent Director by BioTime, Inc., an Independent Non-Executive Director by Elan Corp.
Plc, a Commissioner by US Food & Drug Administration, a Director-National Cancer Institute by National Institutes of Health, a Director-FDA Project by Manhattan Institute For Policy Research, Inc., a Principal by The University of Texas at Austin, and a Director-Prostate Cancer Research by The University of Texas M.D.
Anderson Cancer Center.
He also served on the board at Celularity, Inc. (United States), OncoCyte Corp., National Comprehensive Cancer Network, Inc., National Cancer Institute, Cypher Genomics, Inc. and HistoSonics, Inc. He received his undergraduate degree from St. Joseph's University and a doctorate degree from Georgetown University School of Medicine.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
04/05/2023 | 25 357 ( 0.01% ) | 438 676 $ | 31/03/2024 | |
CELULARITY INC. CLASS A
0.14% | 14/06/2023 | 29 992 ( 0.14% ) | 156 858 $ | 31/03/2024 |
10/08/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Andrew von Eschenbach
Empresas | Cargo | Inicio |
---|---|---|
BAUSCH + LOMB CORPORATION | Director/Board Member | - |
TRISALUS LIFE SCIENCES, INC. | Director/Board Member | 10/08/2023 |
Focused Ultrasound Foundation
Focused Ultrasound Foundation Miscellaneous Commercial ServicesCommercial Services Focused Ultrasound Foundation is an early-sage company, which engages in the provision of non-invasive therapeutic technology. It focuses on cardiovascular, endocrine disorders, gastrointestinal, musculoskeletal, neurological, oncological, urological, and women''s health sectors. The company was founded by Neal F. Kassell and is headquartered in Charlottesville, VA. | Director/Board Member | 09/08/2010 |
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Director/Board Member | - |
Reagan-udall Foundation | Director/Board Member | 01/12/2018 |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 01/11/2019 |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Director/Board Member | - |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Director/Board Member | - |
Samaritan Health Initiatives, Inc. | President | 01/01/2010 |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Antiguos cargos conocidos de Andrew von Eschenbach.
Empresas | Cargo | Fin |
---|---|---|
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formación de Andrew von Eschenbach.
St. Joseph's University | Undergraduate Degree |
Georgetown University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 6 |
---|---|
LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
BAUSCH HEALTH COMPANIES INC. | Health Technology |
ONCOCYTE CORPORATION | Health Technology |
BAUSCH + LOMB CORPORATION | Health Technology |
CELULARITY INC. | Commercial Services |
TRISALUS LIFE SCIENCES, INC. | Health Technology |
Empresas privadas | 23 |
---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
HistoSonics, Inc.
HistoSonics, Inc. Medical SpecialtiesHealth Technology HistoSonics, Inc. develops medical devices. The company was founded by Christine Gibbons, Jim Bertolina, Zhen Xu, William Robert, Hall Timothy, J. Brian Fowlkes, Thomas W. Davison, and Charles Cain in November 2009 and is headquartered in Ann Arbor, MI. | Health Technology |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Asterias Biotherapeutics, Inc.
Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Government |
Banyan Biomarkers, Inc.
Banyan Biomarkers, Inc. Medical/Nursing ServicesHealth Services Banyan Biomarkers, Inc. engages in the commercialization of vitro diagnostic tests for the detection of brain injury and neurological diseases. It develops blood test to accurately and quickly diagnose traumatic brain injury. The company was founded by Nancy Denslow, Ronald L. Hayes, and Kevin Wang in 2002 and is headquartered in San Diego, CA. | Health Services |
National Comprehensive Cancer Network, Inc.
National Comprehensive Cancer Network, Inc. Miscellaneous Commercial ServicesCommercial Services National Comprehensive Cancer Network, Inc. provides research and development services to fight against cancer. The organization develops resources that present information to the numerous stakeholders in the health care delivery system. The company was founded in 1995 and is headquartered in Fort Washington, PA. | Commercial Services |
Manhattan Institute For Policy Research, Inc.
Manhattan Institute For Policy Research, Inc. Miscellaneous Commercial ServicesCommercial Services Manhattan Institute For Policy Research, Inc. develops and disseminate new ideas for greater economic choice and individual responsibility. It focuses on economic growth, education, energy and environment, health care, legal reform, public sector, race and urban policy. The company was founded by Antony Fisher and William J. Casey in 1977 and is headquartered in New York, NY. | Commercial Services |
Focused Ultrasound Foundation
Focused Ultrasound Foundation Miscellaneous Commercial ServicesCommercial Services Focused Ultrasound Foundation is an early-sage company, which engages in the provision of non-invasive therapeutic technology. It focuses on cardiovascular, endocrine disorders, gastrointestinal, musculoskeletal, neurological, oncological, urological, and women''s health sectors. The company was founded by Neal F. Kassell and is headquartered in Charlottesville, VA. | Commercial Services |
Reagan-udall Foundation | |
National Comprehensive Cancer Network Foundation | |
Samaritan Health Initiatives, Inc. | |
Cypher Genomics, Inc.
Cypher Genomics, Inc. Information Technology ServicesTechnology Services Cypher Genomics, Inc. provides automated human genome interpretation software solutions. It offers molecular diagnostics, drug development, and science and technology. The company was founded by Ashley Van Zeeland and Ali Torkamani in 2011 and is headquartered in San Diego, CA. | Technology Services |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Celularity, Inc. (United States)
Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Commercial Services |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
- Bolsa de valores
- Insiders
- Andrew von Eschenbach